25 XP   0   0   10

Regenxbio Inc
Buy, Hold or Sell?

Let's analyse Regenxbio together

PenkeI guess you are interested in Regenxbio Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Regenxbio Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Regenxbio Inc

I send you an email if I find something interesting about Regenxbio Inc.

Quick analysis of Regenxbio (30 sec.)










What can you expect buying and holding a share of Regenxbio? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.36
Expected worth in 1 year
$2.19
How sure are you?
28.9%

+ What do you gain per year?

Total Gains per Share
$-4.17
Return On Investment
-25.9%

For what price can you sell your share?

Current Price per Share
$16.11
Expected price per share
$11.83 - $26.03
How sure are you?
50%

1. Valuation of Regenxbio (5 min.)




Live pricePrice per Share (EOD)

$16.11

Intrinsic Value Per Share

$-82.07 - $-97.89

Total Value Per Share

$-75.71 - $-91.53

2. Growth of Regenxbio (5 min.)




Is Regenxbio growing?

Current yearPrevious yearGrowGrow %
How rich?$311.7m$600m-$213.5m-55.3%

How much money is Regenxbio making?

Current yearPrevious yearGrowGrow %
Making money-$66.6m-$72.6m$5.9m8.9%
Net Profit Margin-305.8%-266.0%--

How much money comes from the company's main activities?

3. Financial Health of Regenxbio (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#175 / 1016

Most Revenue
#222 / 1016

Most Profit
#927 / 1016

Most Efficient
#689 / 1016

What can you expect buying and holding a share of Regenxbio? (5 min.)

Welcome investor! Regenxbio's management wants to use your money to grow the business. In return you get a share of Regenxbio.

What can you expect buying and holding a share of Regenxbio?

First you should know what it really means to hold a share of Regenxbio. And how you can make/lose money.

Speculation

The Price per Share of Regenxbio is $16.11. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Regenxbio.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Regenxbio, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.36. Based on the TTM, the Book Value Change Per Share is $-1.04 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.27 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Regenxbio.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.28-8.0%-1.34-8.3%-1.43-8.9%-0.63-3.9%-0.43-2.6%
Usd Book Value Change Per Share-1.05-6.5%-1.04-6.5%-1.27-7.9%-0.20-1.2%0.171.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.05-6.5%-1.04-6.5%-1.27-7.9%-0.20-1.2%0.171.0%
Usd Price Per Share17.95-18.33-26.75-32.76-28.15-
Price to Earnings Ratio-3.50--3.41--4.66--26.92--13.48-
Price-to-Total Gains Ratio-17.12--17.66--21.25--15.72--38.55-
Price to Book Ratio2.82-2.36-2.18-3.40-3.80-
Price-to-Total Gains Ratio-17.12--17.66--21.25--15.72--38.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share16.11
Number of shares62
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.04-0.20
Usd Total Gains Per Share-1.04-0.20
Gains per Quarter (62 shares)-64.68-12.47
Gains per Year (62 shares)-258.73-49.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-259-2690-50-60
20-517-5280-100-110
30-776-7870-150-160
40-1035-10460-200-210
50-1294-13050-249-260
60-1552-15640-299-310
70-1811-18230-349-360
80-2070-20820-399-410
90-2329-23410-449-460
100-2587-26000-499-510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%5.033.00.013.2%5.033.01.012.8%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%11.025.02.028.9%11.026.02.028.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.038.00.0%0.00.039.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%11.025.02.028.9%11.026.02.028.2%

Fundamentals of Regenxbio

About Regenxbio Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2024-04-12 16:37:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Regenxbio Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Regenxbio earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • A Net Profit Margin of -283.1% means that $-2.83 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Regenxbio Inc:

  • The MRQ is -283.1%. The company is making a huge loss. -2
  • The TTM is -305.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-283.1%TTM-305.8%+22.7%
TTM-305.8%YOY-266.0%-39.8%
TTM-305.8%5Y-384.6%+78.8%
5Y-384.6%10Y-967.7%+583.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-283.1%-199.6%-83.5%
TTM-305.8%-213.0%-92.8%
YOY-266.0%-279.3%+13.3%
5Y-384.6%-438.4%+53.8%
10Y-967.7%-605.5%-362.2%
1.1.2. Return on Assets

Shows how efficient Regenxbio is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • -11.0% Return on Assets means that Regenxbio generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Regenxbio Inc:

  • The MRQ is -11.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.0%TTM-10.2%-0.8%
TTM-10.2%YOY-7.9%-2.3%
TTM-10.2%5Y-5.3%-4.9%
5Y-5.3%10Y-10.7%+5.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.0%-13.5%+2.5%
TTM-10.2%-12.9%+2.7%
YOY-7.9%-11.8%+3.9%
5Y-5.3%-14.1%+8.8%
10Y-10.7%-16.0%+5.3%
1.1.3. Return on Equity

Shows how efficient Regenxbio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • -20.2% Return on Equity means Regenxbio generated $-0.20 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Regenxbio Inc:

  • The MRQ is -20.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.2%TTM-17.5%-2.7%
TTM-17.5%YOY-12.2%-5.3%
TTM-17.5%5Y-8.1%-9.4%
5Y-8.1%10Y-5.6%-2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.2%-16.9%-3.3%
TTM-17.5%-16.1%-1.4%
YOY-12.2%-15.1%+2.9%
5Y-8.1%-19.9%+11.8%
10Y-5.6%-20.9%+15.3%

1.2. Operating Efficiency of Regenxbio Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Regenxbio is operating .

  • Measures how much profit Regenxbio makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • An Operating Margin of -287.7% means the company generated $-2.88  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Regenxbio Inc:

  • The MRQ is -287.7%. The company is operating very inefficient. -2
  • The TTM is -309.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-287.7%TTM-309.7%+22.0%
TTM-309.7%YOY-241.4%-68.2%
TTM-309.7%5Y-475.2%+165.5%
5Y-475.2%10Y-1,062.4%+587.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-287.7%-295.1%+7.4%
TTM-309.7%-225.8%-83.9%
YOY-241.4%-288.4%+47.0%
5Y-475.2%-477.4%+2.2%
10Y-1,062.4%-625.6%-436.8%
1.2.2. Operating Ratio

Measures how efficient Regenxbio is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.88 means that the operating costs are $3.88 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Regenxbio Inc:

  • The MRQ is 3.877. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.060. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.877TTM4.060-0.183
TTM4.060YOY3.414+0.646
TTM4.0605Y5.293-1.233
5Y5.29310Y11.344-6.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8773.090+0.787
TTM4.0603.264+0.796
YOY3.4143.783-0.369
5Y5.2935.679-0.386
10Y11.3447.894+3.450

1.3. Liquidity of Regenxbio Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Regenxbio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.57 means the company has $2.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Regenxbio Inc:

  • The MRQ is 2.571. The company is able to pay all its short-term debts. +1
  • The TTM is 3.030. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.571TTM3.030-0.459
TTM3.030YOY3.628-0.598
TTM3.0305Y6.356-3.326
5Y6.35610Y9.985-3.629
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5713.914-1.343
TTM3.0304.220-1.190
YOY3.6285.388-1.760
5Y6.3566.045+0.311
10Y9.9856.406+3.579
1.3.2. Quick Ratio

Measures if Regenxbio is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • A Quick Ratio of 4.16 means the company can pay off $4.16 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Regenxbio Inc:

  • The MRQ is 4.163. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.805. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.163TTM4.805-0.642
TTM4.805YOY5.515-0.710
TTM4.8055Y9.757-4.952
5Y9.75710Y14.974-5.218
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1633.572+0.591
TTM4.8053.998+0.807
YOY5.5155.390+0.125
5Y9.7575.969+3.788
10Y14.9746.287+8.687

1.4. Solvency of Regenxbio Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Regenxbio assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Regenxbio to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.46 means that Regenxbio assets are financed with 45.7% credit (debt) and the remaining percentage (100% - 45.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Regenxbio Inc:

  • The MRQ is 0.457. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.417. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.457TTM0.417+0.040
TTM0.417YOY0.352+0.065
TTM0.4175Y0.289+0.127
5Y0.28910Y0.361-0.072
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4570.336+0.121
TTM0.4170.334+0.083
YOY0.3520.269+0.083
5Y0.2890.366-0.077
10Y0.3610.390-0.029
1.4.2. Debt to Equity Ratio

Measures if Regenxbio is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Regenxbio to the Biotechnology industry mean.
  • A Debt to Equity ratio of 84.1% means that company has $0.84 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Regenxbio Inc:

  • The MRQ is 0.841. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.719. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.841TTM0.719+0.122
TTM0.719YOY0.545+0.174
TTM0.7195Y0.461+0.258
5Y0.46110Y0.265+0.196
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8410.382+0.459
TTM0.7190.396+0.323
YOY0.5450.335+0.210
5Y0.4610.434+0.027
10Y0.2650.465-0.200

2. Market Valuation of Regenxbio Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Regenxbio generates.

  • Above 15 is considered overpriced but always compare Regenxbio to the Biotechnology industry mean.
  • A PE ratio of -3.50 means the investor is paying $-3.50 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Regenxbio Inc:

  • The EOD is -3.138. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.496. Based on the earnings, the company is expensive. -2
  • The TTM is -3.406. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.138MRQ-3.496+0.358
MRQ-3.496TTM-3.406-0.089
TTM-3.406YOY-4.665+1.258
TTM-3.4065Y-26.922+23.515
5Y-26.92210Y-13.476-13.445
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.138-2.259-0.879
MRQ-3.496-2.569-0.927
TTM-3.406-2.664-0.742
YOY-4.665-4.120-0.545
5Y-26.922-6.258-20.664
10Y-13.476-6.171-7.305
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Regenxbio Inc:

  • The EOD is -4.711. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.249. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.206. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.711MRQ-5.249+0.538
MRQ-5.249TTM-4.206-1.043
TTM-4.206YOY-5.592+1.386
TTM-4.2065Y-7.694+3.488
5Y-7.69410Y-11.503+3.809
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.711-2.924-1.787
MRQ-5.249-3.246-2.003
TTM-4.206-3.488-0.718
YOY-5.592-5.620+0.028
5Y-7.694-8.315+0.621
10Y-11.503-8.826-2.677
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Regenxbio is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.82 means the investor is paying $2.82 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Regenxbio Inc:

  • The EOD is 2.532. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.821. Based on the equity, the company is underpriced. +1
  • The TTM is 2.362. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.532MRQ2.821-0.289
MRQ2.821TTM2.362+0.459
TTM2.362YOY2.182+0.180
TTM2.3625Y3.398-1.036
5Y3.39810Y3.796-0.398
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.5321.851+0.681
MRQ2.8212.090+0.731
TTM2.3622.095+0.267
YOY2.1822.844-0.662
5Y3.3983.466-0.068
10Y3.7963.815-0.019
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Regenxbio Inc.

3.1. Institutions holding Regenxbio Inc

Institutions are holding 82.62% of the shares of Regenxbio Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc18.4740.003882075481810582.2558
2023-12-31Vanguard Group Inc9.99570.00174440838642651.4684
2023-12-31JPMorgan Chase & Co8.86740.006839395492741857.4804
2023-12-31State Street Corporation5.92250.002326312201277395.1025
2023-09-30Redmile Group, LLC5.79382.0159257404254746627.0143
2023-12-31Morgan Stanley - Brokerage Accounts4.09740.002918203821438467376.6459
2023-12-31Dimensional Fund Advisors, Inc.2.76170.00641226957343852.8833
2023-12-31Geode Capital Management, LLC2.09260.0018929672465265.2682
2023-12-31Aquilo Capital Management, LLC1.80618.9768802424-45000-5.3102
2023-09-30Citadel Advisors Llc1.62320.00257211617076510.8803
2023-12-31Goldman Sachs Group Inc1.51310.00116722127535812.6259
2023-09-30Jacobs Levy Equity Management, Inc.1.26590.054856239114930.2662
2023-12-31MPM Oncology Impact Management LP1.23592.3059549078-107640-16.3906
2023-12-31Northern Trust Corp1.00560.0015446773167383.8922
2023-12-31Sonic GP LLC0.99739.1358443079-75000-14.4766
2023-12-31WS Management LLP0.97060.4595431200-186931-30.2413
2023-12-31Ameriprise Financial Inc0.8480.00237672811706045.0806
2023-12-31Perceptive Advisors LLC0.77070.13723424083424080
2023-12-31Bank of New York Mellon Corp0.76030.0012337773-22923-6.3552
2023-12-31Charles Schwab Investment Management Inc0.7370.001532745116830.5166
Total 71.538823.121431782886+2902102+9.1%

3.2. Funds holding Regenxbio Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Core S&P Small-Cap ETF6.21960.0622276322744460.1612
2024-01-31JPMorgan Small Cap Growth A2.89430.43931285847-37591-2.8404
2024-02-29Vanguard Total Stock Mkt Idx Inv2.78930.0014123923700
2024-02-29SPDR® S&P Biotech ETF2.55640.25011135738212401.9058
2024-02-29JPM Global Healthcare C (acc) USD2.39690.44341064900-19077-1.7599
2024-02-29Vanguard Small Cap Index2.29670.0127102037593460.9244
2024-02-29iShares Russell 2000 ETF2.23610.0278993450-162-0.0163
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.33490.01015930574760.0803
2024-02-29Vanguard Small Cap Growth Index Inv1.28930.028657279895231.6906
2024-02-29JPM Thematics Genetic Thrps C2 Acc USD0.99721.0781443019-6703-1.4905
2023-12-31Fidelity Small Cap Index0.91970.028940859495832.4017
2024-02-01iShares Russell 2000 Value ETF0.86520.04133843844860.1266
2024-02-29SPDR® Portfolio S&P 600 Sm Cap ETF0.83320.0629370183750.0203
2024-02-29BlackRock Advantage Small Cap Core Instl0.77350.1708343643-30722-8.2064
2024-02-29Vanguard Tax-Managed Small Cap Adm0.71170.062131620200
2024-02-29iShares Biotechnology ETF0.69160.0705307277-1385-0.4487
2024-02-29iShares S&P Small-Cap 600 Value ETF0.65430.07212907037980.2753
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.55440.010324630236001.4833
2024-01-31JPMorgan Small Cap Blend A0.55410.2215246161-2051-0.8263
2024-01-31Fidelity Extended Market Index0.50850.007822592024341.0891
Total 32.07693.101914251017-35684-0.3%

3.3. Insider Transactions

Insiders are holding 7.426% of the shares of Regenxbio Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-14Kenneth T MillsSELL1500021.86
2024-03-05Steve PakolaSELL1287828.36
2024-02-14Kenneth T MillsSELL1500016.76
2024-01-16Kenneth T MillsSELL4500015.18
2024-01-03Steve PakolaSELL1723717.39
2023-12-19Kenneth T MillsSELL4500019.68

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Regenxbio Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.048-1.0430%-1.266+21%-0.201-81%0.169-722%
Book Value Per Share--6.3637.888-19%12.248-48%9.946-36%7.209-12%
Current Ratio--2.5713.030-15%3.628-29%6.356-60%9.985-74%
Debt To Asset Ratio--0.4570.417+10%0.352+30%0.289+58%0.361+27%
Debt To Equity Ratio--0.8410.719+17%0.545+54%0.461+82%0.265+217%
Dividend Per Share----0%-0%-0%-0%
Eps---1.284-1.345+5%-1.430+11%-0.635-51%-0.425-67%
Free Cash Flow Per Share---0.855-1.165+36%-1.216+42%-0.543-36%-0.316-63%
Free Cash Flow To Equity Per Share---1.099-1.344+22%-1.363+24%-0.196-82%0.151-826%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---97.894--------
Intrinsic Value_10Y_min---82.069--------
Intrinsic Value_1Y_max---3.356--------
Intrinsic Value_1Y_min---3.292--------
Intrinsic Value_3Y_max---15.001--------
Intrinsic Value_3Y_min---14.222--------
Intrinsic Value_5Y_max---32.577--------
Intrinsic Value_5Y_min---29.814--------
Market Cap789274008.000-11%879420760.000897915542.000-2%1310557400.000-33%1605077617.200-45%1378915248.842-36%
Net Profit Margin---2.831-3.058+8%-2.660-6%-3.846+36%-9.677+242%
Operating Margin---2.877-3.097+8%-2.414-16%-4.752+65%-10.624+269%
Operating Ratio--3.8774.060-5%3.414+14%5.293-27%11.344-66%
Pb Ratio2.532-11%2.8212.362+19%2.182+29%3.398-17%3.796-26%
Pe Ratio-3.138+10%-3.496-3.406-3%-4.665+33%-26.922+670%-13.476+285%
Price Per Share16.110-11%17.95018.328-2%26.750-33%32.762-45%28.145-36%
Price To Free Cash Flow Ratio-4.711+10%-5.249-4.206-20%-5.592+7%-7.694+47%-11.503+119%
Price To Total Gains Ratio-15.368+10%-17.123-17.663+3%-21.248+24%-15.724-8%-38.548+125%
Quick Ratio--4.1634.805-13%5.515-25%9.757-57%14.974-72%
Return On Assets---0.110-0.102-7%-0.079-28%-0.053-52%-0.107-3%
Return On Equity---0.202-0.175-13%-0.122-40%-0.081-60%-0.056-72%
Total Gains Per Share---1.048-1.0430%-1.266+21%-0.201-81%0.169-722%
Usd Book Value--311742000.000386459000.000-19%600051750.000-48%487258350.000-36%353193500.000-12%
Usd Book Value Change Per Share---1.048-1.0430%-1.266+21%-0.201-81%0.169-722%
Usd Book Value Per Share--6.3637.888-19%12.248-48%9.946-36%7.209-12%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.284-1.345+5%-1.430+11%-0.635-51%-0.425-67%
Usd Free Cash Flow---41886000.000-57091750.000+36%-59553000.000+42%-26611700.000-36%-15504631.579-63%
Usd Free Cash Flow Per Share---0.855-1.165+36%-1.216+42%-0.543-36%-0.316-63%
Usd Free Cash Flow To Equity Per Share---1.099-1.344+22%-1.363+24%-0.196-82%0.151-826%
Usd Market Cap789274008.000-11%879420760.000897915542.000-2%1310557400.000-33%1605077617.200-45%1378915248.842-36%
Usd Price Per Share16.110-11%17.95018.328-2%26.750-33%32.762-45%28.145-36%
Usd Profit---62889000.000-66692000.000+6%-72601500.000+15%-31765850.000-49%-18380421.053-71%
Usd Revenue--22213000.00022560500.000-2%28181000.000-21%43155650.000-49%29100500.000-24%
Usd Total Gains Per Share---1.048-1.0430%-1.266+21%-0.201-81%0.169-722%
 EOD+3 -5MRQTTM+15 -18YOY+14 -195Y+5 -2810Y+6 -27

4.2. Fundamental Score

Let's check the fundamental score of Regenxbio Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.138
Price to Book Ratio (EOD)Between0-12.532
Net Profit Margin (MRQ)Greater than0-2.831
Operating Margin (MRQ)Greater than0-2.877
Quick Ratio (MRQ)Greater than14.163
Current Ratio (MRQ)Greater than12.571
Debt to Asset Ratio (MRQ)Less than10.457
Debt to Equity Ratio (MRQ)Less than10.841
Return on Equity (MRQ)Greater than0.15-0.202
Return on Assets (MRQ)Greater than0.05-0.110
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Regenxbio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.981
Ma 20Greater thanMa 5019.700
Ma 50Greater thanMa 10019.849
Ma 100Greater thanMa 20018.320
OpenGreater thanClose16.750
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets573,970
Total Liabilities262,228
Total Stockholder Equity311,742
 As reported
Total Liabilities 262,228
Total Stockholder Equity+ 311,742
Total Assets = 573,970

Assets

Total Assets573,970
Total Current Assets334,971
Long-term Assets238,999
Total Current Assets
Cash And Cash Equivalents 34,522
Short-term Investments 240,736
Net Receivables 26,341
Other Current Assets 33,372
Total Current Assets  (as reported)334,971
Total Current Assets  (calculated)334,971
+/-0
Long-term Assets
Property Plant Equipment 192,590
Long Term Investments 38,871
Long-term Assets Other 4,807
Long-term Assets  (as reported)238,999
Long-term Assets  (calculated)236,268
+/- 2,731

Liabilities & Shareholders' Equity

Total Current Liabilities130,272
Long-term Liabilities131,956
Total Stockholder Equity311,742
Total Current Liabilities
Short-term Debt 7,068
Accounts payable 22,786
Other Current Liabilities 100,270
Total Current Liabilities  (as reported)130,272
Total Current Liabilities  (calculated)130,124
+/- 148
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt82,222
Long-term Liabilities Other 49,734
Long-term Liabilities  (as reported)131,956
Long-term Liabilities  (calculated)131,956
+/-0
Total Stockholder Equity
Common Stock4
Retained Earnings -705,047
Accumulated Other Comprehensive Income -4,429
Other Stockholders Equity 1,021,214
Total Stockholder Equity (as reported)311,742
Total Stockholder Equity (calculated)311,742
+/-0
Other
Capital Stock4
Cash and Short Term Investments 275,258
Common Stock Shares Outstanding 44,001
Current Deferred Revenue148
Liabilities and Stockholders Equity 573,970
Net Debt 54,768
Net Invested Capital 311,742
Net Working Capital 204,699
Property Plant and Equipment Gross 249,798
Short Long Term Debt Total 89,290



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-31
> Total Assets 
2,510
0
3,491
0
88,800
227,314
221,380
214,984
206,072
195,975
172,732
224,127
224,376
209,255
198,677
317,217
335,987
514,984
543,814
519,031
529,139
509,237
497,908
463,936
449,738
541,174
708,164
879,442
836,402
800,395
1,113,904
1,025,368
953,444
883,793
833,268
747,830
682,458
633,786
573,970
573,970633,786682,458747,830833,268883,793953,4441,025,3681,113,904800,395836,402879,442708,164541,174449,738463,936497,908509,237529,139519,031543,814514,984335,987317,217198,677209,255224,376224,127172,732195,975206,072214,984221,380227,31488,80003,49102,510
   > Total Current Assets 
0
0
3,031
0
87,089
215,485
118,148
105,580
97,907
96,620
93,371
148,802
165,817
172,161
167,997
262,718
293,270
386,357
337,913
303,884
359,492
360,228
345,032
338,233
329,082
386,950
531,197
498,638
437,387
410,164
518,826
446,877
465,424
436,639
415,976
389,202
378,809
365,838
334,971
334,971365,838378,809389,202415,976436,639465,424446,877518,826410,164437,387498,638531,197386,950329,082338,233345,032360,228359,492303,884337,913386,357293,270262,718167,997172,161165,817148,80293,37196,62097,907105,580118,148215,48587,08903,03100
       Cash And Cash Equivalents 
1,119
0
1,121
0
85,215
205,324
54,116
35,511
30,083
28,108
24,840
82,045
57,649
59,884
46,656
71,870
106,889
142,423
75,561
55,852
55,142
79,594
69,514
69,411
94,222
93,220
338,426
291,482
257,072
228,387
345,209
191,873
121,374
118,544
96,952
70,091
68,600
53,045
34,522
34,52253,04568,60070,09196,952118,544121,374191,873345,209228,387257,072291,482338,42693,22094,22269,41169,51479,59455,14255,85275,561142,423106,88971,87046,65659,88457,64982,04524,84028,10830,08335,51154,116205,32485,21501,12101,119
       Short-term Investments 
0
0
60,025
0
0
8,025
60,025
65,544
64,124
63,662
64,714
63,764
104,434
106,778
114,122
157,997
179,605
230,166
244,200
229,373
286,354
252,125
226,696
209,846
174,964
148,305
137,314
149,398
117,665
111,473
112,230
202,261
281,588
263,874
267,690
261,726
251,482
248,842
240,736
240,736248,842251,482261,726267,690263,874281,588202,261112,230111,473117,665149,398137,314148,305174,964209,846226,696252,125286,354229,373244,200230,166179,605157,997114,122106,778104,43463,76464,71463,66264,12465,54460,0258,0250060,02500
       Net Receivables 
0
0
1,882
0
704
609
2,136
2,036
783
679
1,032
228
50
884
473
25,976
739
2,626
8,587
8,372
9,679
19,175
38,148
44,522
42,876
122,116
42,999
41,039
44,394
46,017
32,439
27,022
37,500
32,549
28,082
18,861
24,980
28,043
26,341
26,34128,04324,98018,86128,08232,54937,50027,02232,43946,01744,39441,03942,999122,11642,87644,52238,14819,1759,6798,3728,5872,62673925,976473884502281,0326797832,0362,13660970401,88200
       Other Current Assets 
0
0
28
0
1,170
127
851
1,300
1,437
2,000
1,010
922
1,252
1,390
1,412
2,208
2,347
4,834
3,831
3,995
2,281
2,414
4,199
7,032
7,271
7,197
1,953
2,880
5,164
5,886
10,196
7,179
8,717
6,848
9,352
23,003
18,635
23,347
33,372
33,37223,34718,63523,0039,3526,8488,7177,17910,1965,8865,1642,8801,9537,1977,2717,0324,1992,4142,2813,9953,8314,8342,3472,2081,4121,3901,2529221,0102,0001,4371,3008511271,17002800
   > Long-term Assets 
0
0
460
0
1,711
11,829
103,232
109,404
108,165
99,355
79,361
75,325
58,559
37,094
30,680
54,499
42,717
128,627
205,901
215,147
169,647
149,009
152,876
125,703
120,656
154,224
176,967
380,804
399,015
390,231
595,078
578,491
488,020
447,154
417,292
358,628
303,649
267,948
238,999
238,999267,948303,649358,628417,292447,154488,020578,491595,078390,231399,015380,804176,967154,224120,656125,703152,876149,009169,647215,147205,901128,62742,71754,49930,68037,09458,55975,32579,36199,355108,165109,404103,23211,8291,711046000
       Property Plant Equipment 
0
0
538
0
312
385
538
1,328
2,864
5,804
9,324
11,061
11,524
11,548
13,977
14,829
16,698
19,856
28,702
29,998
33,234
34,192
39,051
39,789
41,331
96,698
120,282
151,949
168,965
183,973
192,451
195,189
198,978
200,377
206,801
205,299
201,116
197,307
192,590
192,590197,307201,116205,299206,801200,377198,978195,189192,451183,973168,965151,949120,28296,69841,33139,78939,05134,19233,23429,99828,70219,85616,69814,82913,97711,54811,52411,0619,3245,8042,8641,328538385312053800
       Long Term Investments 
0
0
303
0
0
11,316
102,526
107,853
104,810
93,087
69,412
63,742
46,417
24,485
15,616
38,562
24,280
106,896
173,831
159,083
108,194
85,408
103,785
77,361
70,054
51,836
50,076
218,457
218,220
196,370
394,169
372,743
281,107
236,397
200,560
143,009
95,302
62,639
38,871
38,87162,63995,302143,009200,560236,397281,107372,743394,169196,370218,220218,45750,07651,83670,05477,361103,78585,408108,194159,083173,831106,89624,28038,56215,61624,48546,41763,74269,41293,087104,810107,853102,52611,3160030300
       Long-term Assets Other 
0
0
157
0
1,096
128
168
223
491
464
625
522
618
1,061
1,087
33,753
6,224
6,475
26,380
26,066
28,219
29,409
10,040
8,553
9,271
9,254
9,876
13,257
11,830
12,618
10,720
12,643
9,969
12,183
9,931
11,620
7,231
8,002
4,807
4,8078,0027,23111,6209,93112,1839,96912,64310,72012,61811,83013,2579,8769,2549,2718,55310,04029,40928,21926,06626,3806,4756,22433,7531,0871,0616185226254644912231681281,096015700
> Total Liabilities 
4,653
0
9,189
0
6,172
5,506
4,572
6,383
9,897
15,749
10,995
11,229
12,679
14,604
15,648
17,877
18,765
20,927
34,966
31,978
34,547
40,842
47,711
43,784
51,877
125,514
330,411
324,938
329,157
338,981
349,606
335,699
322,925
319,969
317,073
282,691
276,603
270,686
262,228
262,228270,686276,603282,691317,073319,969322,925335,699349,606338,981329,157324,938330,411125,51451,87743,78447,71140,84234,54731,97834,96620,92718,76517,87715,64814,60412,67911,22910,99515,7499,8976,3834,5725,5066,17209,18904,653
   > Total Current Liabilities 
4,653
0
9,189
0
6,038
5,308
4,339
5,781
9,149
14,382
9,669
9,958
11,462
13,399
14,437
14,876
16,853
19,120
22,176
21,390
24,661
31,345
33,676
31,789
40,203
63,613
81,447
83,961
91,554
106,771
130,472
119,937
114,556
123,548
130,434
112,334
117,893
127,346
130,272
130,272127,346117,893112,334130,434123,548114,556119,937130,472106,77191,55483,96181,44763,61340,20331,78933,67631,34524,66121,39022,17619,12016,85314,87614,43713,39911,4629,9589,66914,3829,1495,7814,3395,3086,03809,18904,653
       Short-term Debt 
0
0
2,403
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,397
2,276
2,506
2,421
2,454
3,013
3,564
2,500
1,843
1,709
1,329
1,752
2,121
2,832
3,608
5,997
6,303
6,326
6,639
7,068
7,0686,6396,3266,3035,9973,6082,8322,1211,7521,3291,7091,8432,5003,5643,0132,4542,4212,5062,2762,39700000000000000002,40300
       Short Long Term Debt 
0
0
3,826
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,397
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000002,39700000000000000003,82600
       Accounts payable 
301
0
334
0
925
3,105
1,014
1,113
2,076
5,376
1,543
4,129
3,948
2,594
4,832
5,007
4,230
5,214
4,412
4,204
5,851
9,608
6,409
9,008
10,901
15,244
10,622
11,311
9,354
19,845
11,387
24,708
16,985
25,210
27,213
23,283
11,639
21,859
22,786
22,78621,85911,63923,28327,21325,21016,98524,70811,38719,8459,35411,31110,62215,24410,9019,0086,4099,6085,8514,2044,4125,2144,2305,0074,8322,5943,9484,1291,5435,3762,0761,1131,0143,10592503340301
       Other Current Liabilities 
4,352
0
6,299
0
4,981
2,076
3,198
4,633
7,073
9,006
8,126
5,829
7,514
10,805
9,605
9,869
12,023
13,306
17,164
14,189
13,201
15,898
21,513
16,994
25,839
44,356
67,876
70,412
80,096
85,202
114,000
89,775
88,103
88,827
95,395
81,437
99,480
98,406
100,270
100,27098,40699,48081,43795,39588,82788,10389,775114,00085,20280,09670,41267,87644,35625,83916,99421,51315,89813,20114,18917,16413,30612,0239,8699,60510,8057,5145,8298,1269,0067,0734,6333,1982,0764,98106,29904,352
   > Long-term Liabilities 
0
0
0
0
134
198
233
602
748
1,367
1,326
1,271
1,217
1,205
1,211
3,001
1,912
1,807
12,790
10,588
9,886
9,497
14,035
11,995
11,674
61,901
248,964
240,977
237,603
232,210
219,134
215,762
208,369
196,421
186,639
170,357
158,710
143,340
131,956
131,956143,340158,710170,357186,639196,421208,369215,762219,134232,210237,603240,977248,96461,90111,67411,99514,0359,4979,88610,58812,7901,8071,9123,0011,2111,2051,2171,2711,3261,3677486022331981340000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,854
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000005,854000000000000000000
       Other Liabilities 
0
0
0
0
134
198
233
602
748
1,367
1,326
1,271
1,217
1,205
1,211
3,001
1,912
1,807
6,936
5,105
5,232
5,177
5,161
4,005
4,589
4,440
178,811
165,899
155,220
148,330
134,205
130,194
122,697
111,748
97,837
0
0
0
0
000097,837111,748122,697130,194134,205148,330155,220165,899178,8114,4404,5894,0055,1615,1775,2325,1056,9361,8071,9123,0011,2111,2051,2171,2711,3261,3677486022331981340000
       Deferred Long Term Liability 
0
0
157
0
0
198
0
602
748
1,367
1,326
1,271
1,217
1,205
1,211
1,225
1,192
1,116
1,098
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,0981,1161,1921,2251,2111,2051,2171,2711,3261,36774860201980015700
> Total Stockholder Equity
0
0
-5,698
0
82,628
221,808
216,808
208,601
196,175
180,226
161,737
212,898
211,697
194,651
183,029
299,340
317,222
494,057
508,848
487,053
494,592
468,395
450,197
420,152
397,861
415,660
377,753
554,504
507,245
461,414
764,298
689,669
630,519
563,824
516,195
465,139
405,855
363,100
311,742
311,742363,100405,855465,139516,195563,824630,519689,669764,298461,414507,245554,504377,753415,660397,861420,152450,197468,395494,592487,053508,848494,057317,222299,340183,029194,651211,697212,898161,737180,226196,175208,601216,808221,80882,6280-5,69800
   Retained Earnings -705,047-642,158-580,290-508,229-441,553-381,618-306,134-237,955-161,232-455,255-396,850-339,211-289,072-242,831-251,622-217,860-177,822-151,358-116,774-115,317-83,016-87,322-68,120-78,714-187,756-171,759-151,053-136,580-114,587-94,979-76,825-62,388-51,620-46,444-39,1100-28,80900
   Accumulated Other Comprehensive Income 
0
0
0
0
-15
-26
-719
275
521
853
-33
-572
-646
-553
-715
-903
-771
-874
-720
-59
471
363
205
-580
750
263
-360
-1,368
-1,255
-1,285
-2,569
-11,950
-14,763
-18,256
-15,401
-11,622
-10,098
-7,413
-4,429
-4,429-7,413-10,098-11,622-15,401-18,256-14,763-11,950-2,569-1,285-1,255-1,368-360263750-580205363471-59-720-874-771-903-715-553-646-572-33853521275-719-26-150000
   Capital Surplus 
0
0
0
0
0
268,275
0
270,711
272,476
274,349
276,354
350,047
363,393
366,960
371,497
378,954
386,110
582,249
592,580
602,425
610,891
619,386
627,810
638,588
648,729
658,224
667,181
895,079
905,346
917,950
928,095
939,570
951,412
963,694
0
984,986
0
0
0
000984,9860963,694951,412939,570928,095917,950905,346895,079667,181658,224648,729638,588627,810619,386610,891602,425592,580582,249386,110378,954371,497366,960363,393350,047276,354274,349272,476270,7110268,27500000
   Treasury Stock000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue90,242
Cost of Revenue-54,533
Gross Profit35,70935,709
 
Operating Income (+$)
Gross Profit35,709
Operating Expense-303,837
Operating Income-268,128-268,128
 
Operating Expense (+$)
Research Development214,946
Selling General Administrative88,494
Selling And Marketing Expenses0
Operating Expense303,837303,440
 
Net Interest Income (+$)
Interest Income243
Interest Expense-6,862
Other Finance Cost-2,947
Net Interest Income-9,566
 
Pretax Income (+$)
Operating Income-268,128
Net Interest Income-9,566
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-263,646-272,610
EBIT - interestExpense = -274,990
-263,646
-256,632
Interest Expense6,862
Earnings Before Interest and Taxes (EBIT)-268,128-256,784
Earnings Before Interest and Taxes (EBITDA)-250,808
 
After tax Income (+$)
Income Before Tax-263,646
Tax Provision--43
Net Income From Continuing Ops-260,540-263,603
Net Income-263,494
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses358,370
Total Other Income/Expenses Net4,4829,566
 

Technical Analysis of Regenxbio
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Regenxbio. The general trend of Regenxbio is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Regenxbio's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Regenxbio Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 17.12 < 23.14 < 26.03.

The bearish price targets are: 11.83.

Tweet this
Regenxbio Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Regenxbio Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Regenxbio Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Regenxbio Inc. The current macd is -0.94483171.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Regenxbio price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Regenxbio. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Regenxbio price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Regenxbio Inc Daily Moving Average Convergence/Divergence (MACD) ChartRegenxbio Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Regenxbio Inc. The current adx is 28.14.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Regenxbio shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Regenxbio Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Regenxbio Inc. The current sar is 18.73.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Regenxbio Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Regenxbio Inc. The current rsi is 25.98. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Regenxbio Inc Daily Relative Strength Index (RSI) ChartRegenxbio Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Regenxbio Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Regenxbio price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Regenxbio Inc Daily Stochastic Oscillator ChartRegenxbio Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Regenxbio Inc. The current cci is -152.12967903.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Regenxbio Inc Daily Commodity Channel Index (CCI) ChartRegenxbio Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Regenxbio Inc. The current cmo is -71.21513515.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Regenxbio Inc Daily Chande Momentum Oscillator (CMO) ChartRegenxbio Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Regenxbio Inc. The current willr is -98.91304348.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Regenxbio Inc Daily Williams %R ChartRegenxbio Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Regenxbio Inc.

Regenxbio Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Regenxbio Inc. The current atr is 1.19475231.

Regenxbio Inc Daily Average True Range (ATR) ChartRegenxbio Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Regenxbio Inc. The current obv is 5,843,585.

Regenxbio Inc Daily On-Balance Volume (OBV) ChartRegenxbio Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Regenxbio Inc. The current mfi is 9.754317.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Regenxbio Inc Daily Money Flow Index (MFI) ChartRegenxbio Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Regenxbio Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Regenxbio Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Regenxbio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.981
Ma 20Greater thanMa 5019.700
Ma 50Greater thanMa 10019.849
Ma 100Greater thanMa 20018.320
OpenGreater thanClose16.750
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Regenxbio with someone you think should read this too:
  • Are you bullish or bearish on Regenxbio? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Regenxbio? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Regenxbio Inc

I send you an email if I find something interesting about Regenxbio Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Regenxbio Inc.

Receive notifications about Regenxbio Inc in your mailbox!